blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2493926

EP2493926 - FUNCTION MODIFYING NAV 1.7 ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.01.2021
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  07.02.2020
FormerGrant of patent is intended
Status updated on  23.10.2019
FormerExamination is in progress
Status updated on  23.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels / BE
[2020/11]
Former [2020/02]For all designated states
UCB Biopharma SRL
Allé de la Recherche 60
1070 Brussels / BE
Former [2015/30]For all designated states
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels / BE
Former [2012/36]For all designated states
UCB Pharma, S.A.
60, allée de la Recherche
1170 Brussels / BE
Inventor(s)01 / MILLER, Karen Margrete
UCB Pharma S.A.
60 Allée de la Recherche
B-1070 Brussels / BE
02 / DE RYCK, Marc Roger
UCB Pharma S.A.
60 Allée de la Recherche
B-1070 Brussels / BE
03 / WOLFF, Christian Gilbert J.
UCB Pharma S.A.
60 Allée de la Recherche
B-1070 Brussels / BE
04 / LAWSON, Alastair David Griffiths
UCB Celltech
208 Bath Road
Slough
Berkshire SL1 3WE / GB
05 / FINNEY, Helene Margaret
UCB Celltech
208 Bath Road
Slough
Berkshire SL1 3WE / GB
06 / BAKER, Terence Seward
UCB Celltech
208 Bath Road
Slough
Berkshire SL1 3WE / GB
 [2012/36]
Representative(s)UCB Intellectual Property
c/o UCB Celltech
IP Department
208 Bath Road
Slough, Berkshire SL1 3WE / GB
[2020/11]
Former [2012/36]Blanchard, Amanda Jane
UCB Celltech 208 Bath Road
Slough, Berkshire SL1 3WE / GB
Application number, filing date10770839.827.10.2010
[2020/11]
WO2010EP66276
Priority number, dateUS20090255202P27.10.2009         Original published format: US 255202 P
[2012/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011051350
Date:05.05.2011
Language:EN
[2011/18]
Type: A1 Application with search report 
No.:EP2493926
Date:05.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
[2012/36]
Type: B1 Patent specification 
No.:EP2493926
Date:11.03.2020
Language:EN
[2020/11]
Search report(s)International search report - published on:EP05.05.2011
ClassificationIPC:C07K16/28
[2012/36]
CPC:
C07K16/28 (EP,US); A61K39/3955 (US); A61P25/04 (EP);
A61P29/00 (EP); A61P43/00 (EP); A61K2039/505 (US);
C07K2317/21 (US); C07K2317/24 (US); C07K2317/31 (US);
C07K2317/34 (US); C07K2317/54 (US); C07K2317/55 (US);
C07K2317/56 (US); C07K2317/565 (EP,US); C07K2317/622 (US);
C07K2317/76 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/36]
Extension statesBA29.05.2012
ME29.05.2012
TitleGerman:FUNKTIONELLE MODIFIZIERUNG VON NAV1.7-ANTIKÖRPERN[2012/36]
English:FUNCTION MODIFYING NAV 1.7 ANTIBODIES[2012/36]
French:MODIFICATION FONCTIONNELLE DES ANTICORPS ANTI-NAV 1.7[2012/36]
Entry into regional phase29.05.2012National basic fee paid 
29.05.2012Designation fee(s) paid 
29.05.2012Examination fee paid 
Examination procedure29.05.2012Examination requested  [2012/36]
13.12.2012Amendment by applicant (claims and/or description)
21.12.2016Despatch of a communication from the examining division (Time limit: M06)
28.06.2017Reply to a communication from the examining division
06.02.2018Despatch of a communication from the examining division (Time limit: M06)
14.08.2018Reply to a communication from the examining division
23.09.2019Cancellation of oral proceeding that was planned for 01.10.2019
01.10.2019Date of oral proceedings (cancelled)
24.10.2019Communication of intention to grant the patent
30.01.2020Fee for grant paid
30.01.2020Fee for publishing/printing paid
30.01.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.12.2016
Opposition(s)14.12.2020No opposition filed within time limit [2021/07]
Fees paidRenewal fee
31.10.2012Renewal fee patent year 03
31.10.2013Renewal fee patent year 04
31.10.2014Renewal fee patent year 05
02.11.2015Renewal fee patent year 06
31.10.2016Renewal fee patent year 07
02.11.2017Renewal fee patent year 08
31.10.2018Renewal fee patent year 09
31.10.2019Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.10.2010
AL11.03.2020
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MK11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
IE27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
[2022/31]
Former [2022/30]HU27.10.2010
AL11.03.2020
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
IE27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2022/27]HU27.10.2010
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
IE27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2022/26]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
IE27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2021/46]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
IE27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2021/38]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB27.10.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2021/37]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.10.2020
BE31.10.2020
CH31.10.2020
FR31.10.2020
LI31.10.2020
Former [2021/36]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.10.2020
BE31.10.2020
FR31.10.2020
Former [2021/35]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.10.2020
FR31.10.2020
Former [2021/31]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.10.2020
Former [2021/10]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2021/09]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2021/08]CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/50]CZ11.03.2020
EE11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/49]CZ11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/48]FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
RS11.03.2020
SE11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/47]FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RS11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/46]FI11.03.2020
HR11.03.2020
LV11.03.2020
NL11.03.2020
RS11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/45]FI11.03.2020
HR11.03.2020
LV11.03.2020
NL11.03.2020
RS11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
Former [2020/39]FI11.03.2020
HR11.03.2020
LV11.03.2020
RS11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
Former [2020/38]FI11.03.2020
HR11.03.2020
LV11.03.2020
RS11.03.2020
SE11.03.2020
NO11.06.2020
GR12.06.2020
Former [2020/37]FI11.03.2020
HR11.03.2020
LV11.03.2020
RS11.03.2020
SE11.03.2020
NO11.06.2020
Former [2020/35]FI11.03.2020
NO11.06.2020
Cited inInternational search[XA]WO2007109324  (XENON PHARMACEUTICALS INC [CA], et al) [X] 1 * abstract * [A] 2-30;
 [A]WO2009033027  (MEDTRONIC INC [US], et al) [A] 1-30 * abstract *;
 [XA]  - MCGOWAN ERIN ET AL, "A Peripherally Acting Na(v)1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain", ANESTHESIA & ANALGESIA, (200909), vol. 109, no. 3, ISSN 0003-2999, pages 951 - 958, XP002618055 [X] 1 * the whole document * [A] 2-30

DOI:   http://dx.doi.org/10.1213/ane.0b013e3181b01b02
 [A]  - MEIRI ET AL, "Detection of cell surface sodium channels by monoclonal antibodies - could the channels become exposed to the external surface and 'down regulated' by binding to antibodies?", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 368, no. 1, doi:DOI:10.1016/0006-8993(86)91061-9, ISSN 0006-8993, (19860312), pages 188 - 192, (19860312), XP024274584 [A] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1016/0006-8993(86)91061-9
ExaminationWO2007023298
 WO2006040357
    - CHIONI A M ET AL, "A novel polyclonal antibody specific for the Nav1.5 voltage-gated Na<+> channel 'neonatal' splice form", JOURNAL OF NEUROSCIENCE METHODS, ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM, NL, vol. 147, no. 2, ISSN 0165-0270, (20050930), pages 88 - 98, (20050930), XP027670521
    - XU SHANG-ZHONG ET AL, "Generation of functional ion-channel tools by E3 targeting", NATURE BIOTECHNOLOGY, GALE GROUP INC, (20051001), vol. 23, no. 10, doi:10.1038/NBT1148, ISSN 1087-0156, pages 1289 - 1293, XP002415111

DOI:   http://dx.doi.org/10.1038/nbt1148
by applicantWO9202551
 WO2004051268
 WO2004106377
 WO9109967
 WO2005003169
 WO2005003170
 WO2005003171
 WO2010035012
 WO9222853
 WO2005113605
 WO9749805
 WO03050531
 US2007041972
 WO2008090958
 US2004191265
 US5585089
 WO9002809
 WO9110737
 WO9201047
 WO9218619
 WO9311236
 WO9515982
 WO9520401
 US5698426
 US5223409
 US5403484
 US5580717
 US5427908
 US5750753
 US5821047
 US5571698
 US5516637
 US5780225
 US5658727
 US5733743
 US5969108
 EP0546073
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 US5770429
 EP0438474
 EP0463151
 US4816397
 US6331415
 EP0996622
 US7456187
 US4741900
 WO2005117984
 US5219996
 US5667425
 WO9825971
 WO2008038024
 US5677425
 US7521541
 WO9820734
    - DOYLE ET AL., SCIENCE, (1998), vol. 280, page 69
    - JIANG ET AL., NATURE, (2003), vol. 423, page 33
    - LONG ET AL., SCIENCE, (2005), vol. 309, page 897
    - LLINAS ET AL., J. PHYSIOL., (1980), vol. 305, pages 197 - 213
    - KOSTYUK ET AL., NEUROSCIENCE, (1981), vol. 6, pages 2423 - 2430
    - BOSSU ET AL., NEUROSCI. LETT., (1981), vol. 51, pages 241 - 246
    - GILLY ET AL., NATURE, (1984), vol. 309, pages 448 - 450
    - FRENCH ET AL., NEUROSCI. LETT., (1985), vol. 56, pages 289 - 294
    - IKEDA ET AL., J. NEUROPHYSIOL., (1986), vol. 55, pages 527 - 539
    - JONES ET AL., J. PHYSIOL., (1987), vol. 389, pages 605 - 627
    - GILLY ET AL., J. NEUROSCI., (1989), vol. 9, pages 1362 - 1374
    - GONOI ET AL., J. NEUROSCI., (1985), vol. 5, pages 2559 - 2564
    - WEISS ET AL., SCIENCE, (1986), vol. 233, pages 361 - 364
    - PNAS, (20011106), vol. 98, no. 23, pages 13373 - 13378
    - THE JOURNAL OF NEUROSCIENCE 22, (2004), vol. 24, no. 38, pages 832 - 836
    - KLIONSKY ET AL., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2006), vol. 319, no. 1, pages 192 - 198
    - BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, no. 15, pages 7843 - 7848
    - CHOTHIA, C.; LESK, A.M., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 535 - 539
    - REICHMANN ET AL., NATURE, (1998), vol. 332, pages 323 - 324
    - HOLLIGER; HUDSON, NATURE BIOTECH., (2005), vol. 23, no. 9, pages 1126 - 1136
    - ADAIR; LAWSON, DRUG DESIGN REVIEWS - ONLINE, (2005), vol. 2, no. 3, pages 209 - 217
    - VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (1998), vol. 216, pages 165 - 181
    - HAMERS ET AL., NATURE, (1993), vol. 363, pages 446 - 448
    - MUYLDERMANS ET AL., TRENDS. BIOCHEM.SCI., (2001), vol. 26, pages 230 - 235
    - DECANNIERE ET AL., J. MOL.BIOL, (2000), vol. 300, pages 83 - 91
    - NGUYEN ET AL., ADV. IMMUNOL., (2001), vol. 79, pages 261 - 296
    - LAUWEREYS ET AL., EMBO J, (1998), vol. 17, pages 3512 - 3520
    - DESMYTER ET AL., NAT.STRUCT.BIOL., (1996), vol. 3, pages 803 - 811
    - DE GENST ET AL., PNAS, (2006), vol. 103, no. 12, pages 4586 - 4591
    - STANFIELD ET AL., SCIENCE, (2004), vol. 305, pages 1770 - 1773
    - LAUWEREYS ET AL., EMBO J., (1998), vol. 17, no. 13, pages 3512 - 20
    - LIU ET AL., BMC BIOTECHNOL., (2007), vol. 7, page 78
    - SAERENS ET AL., J. BIOL. CHEM., (2004), vol. 279, no. 5, pages 51965 - 72
    - TAO ET AL., J. EXP.MED, (1991), vol. 173, pages 1025 - 1028
    - TAO ET AL., J. EXP.MED, (1993), vol. 178, pages 661 - 667
    - ZUCKER ET AL., CANC RES, (1998), vol. 58, pages 3905 - 3908
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 72
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), pages 77 - 96
    - BRINKMAN ET AL., J IMMUNOL. METHODS, (1995), vol. 182, pages 41 - 50
    - AMES ET AL., J LMMUNOL. METHODS, (1995), vol. 184, pages 177 - 186
    - KETTLEBOROUGH ET AL., EUR. J IMMUNOL., (1994), vol. 24, pages 952 - 958
    - PERSIC ET AL., GENE, (1997), vol. 187, pages 9 - 18
    - BURTON ET AL., ADVANCES IN IMMUNOLOGY, (1994), vol. 57, pages 191 - 280
    - WARD ET AL., NATURE, (1989), vol. 341, page 544
    - ORLANDI ET AL., PROC.NATL.ACAD.SCI. USA, (1989), vol. 86, page 3833
    - RIECHMANN ET AL., NATURE, (1988), vol. 322, page 323
    - BIRD ET AL., SCIENCE, (1988), vol. 242, page 423
    - MOUNTAIN; ADAIR, BIOTECHNOL. GENET. ENG. REV, (1992), vol. 10, pages 1 - 142
    - ANGAL ET AL., MOLECULAR IMMUNOLOGY, (1993), vol. 30, no. 1, pages 105 - 108
    - HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, (1995), vol. 705, pages 129 - 134
    - NYGREN; UHLEN, CURRENT OPINION IN STRUCTURAL BIOLOGY, (1997), vol. 7, pages 463 - 469
    - MOL PHARMACOL, (2008), vol. 74, pages 1476 - 1484
    - RA HILL; S RUDRA; B PENG; DS ROANE; JK BOUNDS; Y G, A ADLOO; T LU, BIOORG MED CHEM, (2003), vol. 11, pages 2099 - 113
    - MCGOWAN ET AL., ANESTHESIA AND ANALGESIA, (200909), vol. 109, no. 3
    - ANGER ET AL., J. MED. CHEM., (2001), vol. 44, no. 2, page 115
    - HOYT ET AL., BIOORG. MED. CHEM. LETT., (2007), vol. 17, page 6172
    - YANG ET AL., J. MED. CHEM., (2004), vol. 47, page 1547
    - BENES ET AL., J. MED. CHEM., (1999), vol. 42, page 2582
    - BIOORGANIC AND MEDICAL CHEMISTRY LETTERS, (20090601), vol. 19, no. 11, pages 3063 - 3066
    - CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, (2002), vol. 54, pages 531 - 545
    - LEONG ET AL., CYTOKINE, (2001), vol. 16, pages 106 - 119
    - CHAPMAN ET AL., NATURE BIOTECHNOLOGY, (1999), vol. 17, pages 780 - 783
    - BARLOS, K.; GATOS, D.; KUTSOGIANNI, S.; PAPAPHOTIOU, G.; POULOS, C.; TSEGENIDIS, T., INT. J. PEPT. PROTEIN RES., (1991), vol. 38, no. 6, pages 562 - 568
    - KESSLER H ET AL., COMPUTER AIDED DRUG DESIGN, (1989), pages 461 - 484
    - DEKKER M ET AL., J. PEPTIDE RESEARCH, (1990), vol. 35, pages 287 - 300
    - GURRATH M. ET AL., EUR. J. BIOCHEM., (1992), vol. 210, pages 911 - 921
    - IZUMIYA N. ET AL., BIOPOLYMERS, (1981), vol. 20, pages 1785 - 1791
    - BRADY S. F. ET AL., Peptides, Structure and Function, PIERCE CHEMICAL COMPANY, (1983), pages 127 - 130
    - HE J. X. ET AL., LETT. PEPTIDE SCI., (1994), vol. 1, pages 25 - 30
    - KESSLER H ET AL., Computer-aided drug design, methods and applications, MARCEL DEKKER, (1989), pages 461 - 484
    - TONIOLO C., INT. J. PEPT. PROTEIN RES., (1990), vol. 35, pages 287 - 300
    - TICKLE ET AL., JALA, (2009), vol. 14, no. 5, pages 303 - 307
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.